Pharmacologic Management of Malignant Bowel Obstruction: When Surgery Is Not an Option.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 30986183.
- Also identified by DOI 10.12788/jhm.3187.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Malignant bowel obstruction (MBO) complicates 3%-15% of cancers and often necessitates inpatient admission. Hospitalists are increasingly involved in treating patients with MBO and coordinating their care across multiple subspecialties. Direct resolution of the obstruction via surgical or interventional means is always preferable. When such options are not possible, pharmacological treatments are the mainstay of therapy. Medications such as somatostatin analogs, steroids, H2-blockers, and other modalities can be effective in palliation and possible resolution of obstruction. Awareness of these pharmacologic therapies can aid hospitalists in treating patients who are confronted with this devastating condition.
Medical subject headings
- Anti-Inflammatory Agents
- Anti-Ulcer Agents
- Dexamethasone
- Gastrointestinal Neoplasms
- Histamine H2 Antagonists
- Intestinal Obstruction
- Ranitidine